FDA authorizes marketing of diagnostic test that uses novel technology to detect MRSA bacteria | FDA

FDA authorizes marketing of diagnostic test that uses novel technology to detect MRSA bacteria | FDA

FDA authorizes marketing of diagnostic test that uses novel technology to detect MRSA bacteria

On December 5, 2019, FDA authorized marketing of a new culture-based diagnostic test that uses novel technology to detect Methicillin-resistant Staphylococcus aureus (MRSA) bacterial colonization,  a widespread cause of hospital-acquired infections. The cobas vivoDx MRSA diagnostic test may allow health care professionals to evaluate patients for colonization with MRSA bacteria more quickly than traditional culture-based techniques when such testing is needed.